Table 1. Prevalence of choroidal neovascularization (CNV) and associated risk factors at cohort entry for patients with posterior or panuveitis.
| Characteristic | Number of Eyes |
Number of Eyes with CNV |
Prevalence | Crude Odds Ratio (95% Confidence Interval) |
Crude p-value |
Adjusted Odds Ratioa (95% Confidence Interval) |
Overall adjusted p-value |
|---|---|---|---|---|---|---|---|
|
Age at uveitis diagnosis, years |
0.81 | 0.43 | |||||
| ≤35 | 1784 | 38 | 2.1% | Reference | Reference | ||
| >35 | 2255 | 43 | 1.9% | 0.94 (0.56-1.57) | 0.81 (0.48-1.35) | ||
| Gender | 0.57 | 0.81 | |||||
| Male | 1437 | 26 | 1.8% | Reference | Reference | ||
| Female | 2604 | 55 | 2.1% | 1.17 (0.68-2.02) | 1.07 (0.62-1.87) | ||
| Race | 0.05 | 0.25 | |||||
| White | 2833 | 62 | 2.2% | Reference | Reference | ||
| Black | 534 | 9 | 1.7% | 0.76 (0.35-1.67) | 1.18 (0.54-2.56) | ||
| Hispanic | 251 | 7 | 2.8% | 1.33 (0.54-3.25) | 1.66 (0.69-4.00) | ||
| Other | 423 | 3 | 0.7% | 0.33 (0.10-1.10) | 0.48 (0.15-1.53) | ||
| Smoking | 0.02 | 0.03 | |||||
| Never | 2027 | 53 | 2.6% | Reference | Reference | ||
| Past | 528 | 11 | 2.1% | 0.74 (0.33-1.66) | 0.76 (0.34-1.71) | ||
| Current | 778 | 7 | 0.9% | 0.35 (0.14-0.84) | 0.34 (0.14-0.83) | ||
| Unknown | 708 | 10 | 1.4% | 0.51 (0.24-1.08) | 0.62 (0.29-1.33) | ||
| Uveitis Category | <0.01 | <0.01 | |||||
| Posterior Uveitis | 2512 | 69 | 2.7% | Reference | Reference | ||
| Panuveitis | 1529 | 12 | 0.8% | 0.29 (0.15-0.56) | 0.26 (0.14-0.51) | ||
|
Posterior/Panuveitis
Subtype b |
<0.01 | <0.01 | |||||
| Undifferentiated Panuveitis |
1159 | 11 | 0.9% | Reference | Reference | ||
| Multifocal Choroiditis with Panuveitis |
615 | 28 | 4.6% | 4.55 (2.04- 10.14) |
4.27 (1.94-9.39) | ||
| Multiple Evanescent White Dot Syndrome |
21 | 3 | 14.3% | 18.58 (4.60- 75.11) |
26.98 (6.25-116.40) | ||
| Birdshot Retinochoroiditis |
397 | 4 | 1.0% | 0.99 (0.31-3.19) | 1.19 (0.34-4.18) | ||
| Vogt-Koyanagi-Harada Syndrome |
320 | 1 | 0.3% | 0.30 (0.04-2.35) | 0.22 (0.03-1.73) | ||
| Retinal Vasculitis | 727 | 6 | 0.8% | 0.78 (0.23-2.63) | 0.95 (0.28-3.15) | ||
| Punctate Inner Choroiditis |
17 | 2 | 11.8% | 15.03 (5.05- 44.79) |
15.90 (5.11-49.43) | ||
| Serpiginous Choroiditis | 148 | 7 | 4.7% | 5.27 (1.82- 15.25) |
5.69 (1.93-16.82) | ||
| Otherc | 637 | 19 | 3.0% | 2.39 (0.98-5.80) | 2.43 (1.02-5.81) | ||
| Bilateral Uveitis | 0.12 | 0.15 | |||||
| No | 389 | 13 | 3.3% | Reference | Reference | ||
| Yes | 3652 | 68 | 1.9% | 0.55 (0.29-1.03) | 0.58 (0.31-1.09) | ||
| Visual Acuity | <0.01 | <0.01 | |||||
| 20/40 or better | 1695 | 17 | 1.0% | Reference | Reference | ||
| >20/40 to <20/200 | 1429 | 35 | 2.4% | 3.25 (1.60-6.60) | 3.24 (1.69-6.23) | ||
| 20/200 or worse | 907 | 29 | 3.2% | 3.88 (1.87-8.05) | 4.06 (2.06-7.99) | ||
| Missing | 10 | 0 | 0.0% | n/a | n/a |
a
Adjusted by race, smoking, uveitis category, and visual acuity
b
Posterior/panuveitis subtype was not adjusted by uveitis category as they are different ways of considering the same variable.
c
The “other” designation includes several conditions too infrequent to analyze separately: Sympathetic Ophthalmia, acute posterior multifocal placoid pigment epitheliopathy (APMPPE), neuroretinitis, diffuse retinochoroiditis, focal retinochoroiditis, acute retinal necrosis syndrome, Eales' Disease, unspecified inflammatory chorioretinal scars, sarcoidosis, and necrotizing retinitis.